DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

February 02, 2015 08:30 ET

DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases

MINNEAPOLIS, MINNESOTA--(Marketwired - Feb. 2, 2015) - DiaMedica Inc. (TSX VENTURE:DMA) today, announced that the company will pursue the development of DM199, its recombinant form of the naturally occurring protein, tissue kallikrein-1 in acute vascular disease of the brain, kidney and heart. The primary focus will be on acute ischemic stroke and acute kidney injury indications.

Stroke represents an area of tremendous unmet medical need. Published pre-clinical and clinical research with a naturally occuring tissue kallikrein-1 has demonstrated reduced blood pressure, cell death, inflammation and increased angiogenesis (creation of new blood vessels). As such DiaMedica's recombinant form of tissue kallikrein-1 has the potential to treat a broad spectrum of clinical scenarios where re-establishing blood flow and reducing inflammation in patients is vital to preserving organ function (e.g. brain, kidney and heart). Lower tissue kallikrein-1 levels in the blood have been independently associated with first-ever stroke and are an independent predictor of recurrence after an initial stroke.

"DM199 is a very promising potential rescue therapy for vascular diseases in patients where improving blood flow and preserving organ function of the brain, kidney and heart is critical," stated Dr. Michael Giuffre, DiaMedica board member and cardiologist.

"We are excited about the potential of DM199 in light of the clinical results with the naturally occurring version of tissue kallikrein-1 for the treatment of stoke," said Mr. Pauls, President & CEO of DiaMedica. "We intend to act expeditiously to move DM199 into clinical trials for stroke."

About DiaMedica

DiaMedica is a publicly traded (TSX VENTURE:DMA) development stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat vascular and metabolic diseases. DiaMedica's lead product, DM199, is recombinant human tissue kallikrein-1 protein (rhKLK1). DiaMedica's common shares are listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward looking statements in this news release include, but are not limited to, the Company's objectives, goals, future plans and statements regarding its restructuring measures. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: uncertainties associated with raising additional capital, its ability to satisfy its current contractual obligations; timing and success of implementing current proposed restructuring measures and any future measures; and the additional risk factors described in detail in the Prospectus and DiaMedica's other filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Contact Information